PIK3CA and small cell lung carcinoma: As expected, we observed that CUDC-907 inhibited the PI3K pathway, as indicated by the dose-dependent decreases in phosphorylation of AKT and its downstream targets, p-4EBP-1, and p-S6RP in all SCLC cell lines tested (Fig. 1d & Supplementary Fig. 1).